Loading
London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma.
Darren Hargrave is a paediatric neuro-oncologist at Great Ormond Street Hospital and a leader of European paediatric drug-development consortia. He was first author of the 2023 Journal of Clinical Oncology report of the phase 2 trial in which dabrafenib plus trametinib produced responses in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma, and a senior investigator on the trial that established the same combination for paediatric low-grade glioma.
| Title | Journal | Year |
|---|---|---|
| Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma | Journal of Clinical Oncology | 2023 |
Shares Childhood cancers (all types) and the tags paediatric, brain, targeted-therapy, trialist.
Shares Paediatric high-grade glioma (excluding diffuse midline glioma), Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares Childhood cancers (all types) and the tags paediatric, brain, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares the tags brain, trialist.
Shares the tags brain, trialist.
Shares the tags brain, trialist.